TuHURA Biosciences, Inc. announced the presentation of new research on the Delta Opioid Receptor (DOR) as a novel target for overcoming acquired resistance to cancer immunotherapy. The results were presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The company reported that DOR is expressed on tumor-associated myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), and that inhibition of DOR reduces the immunosuppressive capabilities of these cells. TuHURA also highlighted the development of a library of selective and potent DOR antagonists and plans to advance a lead antibody drug conjugate $(ADC)$ candidate consisting of a DOR inhibitor linked to a VISTA inhibiting antibody. The company stated that these ADCs have the potential to modulate the tumor microenvironment and support immune recognition of leukemic cells.